Oncopeptides AB
STO:ONCO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (26.8), the stock would be worth kr-14.31 (1 171% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -2.5 | kr1.34 |
0%
|
| Industry Average | 26.8 | kr-14.31 |
-1 171%
|
| Country Average | 17.8 | kr-9.5 |
-811%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| SE |
|
Oncopeptides AB
STO:ONCO
|
518.2m SEK | -2.5 | -2.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -192 227.3 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
355.3B USD | 19.5 | 83.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.9B USD | 14 | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
165.8B USD | 14.7 | 19 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.5B USD | 21.6 | 27.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -565.5 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81B USD | 14.9 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 41.1 | 37.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -60.1 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.2B AUD | 13.2 | 30.9 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 14 |
| Median | 17.8 |
| 70th Percentile | 23.3 |
| Max | 4 325.3 |
Other Multiples
Oncopeptides AB
Glance View
Oncopeptides AB is a pharmaceutical company focused on the development of targeted therapies for hematological diseases. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2017-02-22. The Company’s lead product candidate PEPAXTO (melphalan flufenamide, also known as melflufen) has been approved in relapsed or refractory multiple myeloma by The U.S. Food and Drug Administration. Melphalan flufenamide is the first drug originated from the Company PDC-platform and is evaluated in a clinical study program, including the ongoing phase 3 OCEAN study. Melphalan flufenamide is an anticancer peptide-drug conjugate for patients with relapsed or refractory multiple myeloma. The drug uses technology that links a peptide carrier to a cytotoxic agent, resulting in a lipophilic compound. Due to its high lipophilicity, it is distributed into the cells. Melphalan flufenamide is designed to leverage aminopeptidases, enzymes which are overexpressed in myeloma cells and cause the release of the cytotoxic agents in the cells.
